• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [25471 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Transmural care for hand eczema; a randomised controlled trial and cost-effectiveness evaluation]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Transjugular intrahepatic porto-systemic shunt (TIPS) with Gore-tex covered stent-graft versus endoscopic treatment for acute bleeding of esophageal varices]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2013     The Swedish Council on Health Technology Assessment (SBU) [Transient elastography in fibrosis staging]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography (FibroScan®) for liver fibrosis staging]
2009     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Transient elastography (Fibroscan) for the diagnosis of liver fibrosis: a systematic review and meta-analysis]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy –Third addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy – Second addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy - Addendum to Commission E16-03]
2023     Haute Autorite de sante (HAS) [Transcutaneous ultrasound-guided intravenous radiofrequency occlusion of the small saphenous vein]
2007     Andalusian Health Technology Assessment Area (AETSA) [Transcutaneous biosensors]
2011     Haute Autorite de sante (HAS) [Transcutaneous aortic valve implantation by the transfemoral or transapical route]
2008     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Transcranial magnetic stimulation]
2025     Andalusian Health Technology Assessment Area (AETSA) [Transcranial magnetic stimulation on cerebellar ataxia: efficacy and safety. A systematic review]
2009     The Swedish Council on Health Technology Assessment (SBU) [Transcranial magnetic stimulation in treating depression]
2020     Canary Health Service [Transcranial magnetic stimulation for the treatment of cocaine addiction]
2022     Haute Autorite de sante (HAS) [Transcranial magnetic stimulation (rTMS) in the treatment of adult treatment-resistant depression]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Second addendum to commission H20-05]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2022     Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2023     Canary Health Service [Transcranial direct current stimulation device for the treatment of drug-resistant epilepsy]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa (Addendum to commission E14-07)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Addendum to commission H21-14]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter mitral valve-in-valve implantation (TMViVI)]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation (MitraClip®, Carillon®, NeoChord DS1000). German short version of the correspondent EUnetHTA assessment]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Transcatheter closure paravalvular leaks with Amplatzer]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Transcatheter aortic valve prosthesis implantation (TAVI)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation in severe aortic stenosis]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation for severe aortic stenosis]
2015     Center for Drug Evaluation (CDE) [Transcatheter aortic valve implantation (TAVI) HTA report]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic prothesis implantation for the treatment of severe aortic stenosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Transapical and transfemoral aortic valve implantation: proposal of indicators for post-introduction observation]
2011     Committee for New Health Technology Assessment (CNHTA) [Transanal radiofrequency treatment of fecal incontinence]
2009     Committee for New Health Technology Assessment (CNHTA) [Transanal endoscopic microsurgery(TEM)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Transanal endoscopic microsurgery (tem) and transanal minimally invasive surgery (tamis) for the treatment of rectal lesions]
2017     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) [Trancatheter ablation with cryoballoon for the treatment of atrial fibrillation. A rapid assessment]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Addendum to Commission A18-60]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Training therapy in physical medicine – Systematic Review]
2011     Finnish Office for Health Care Technology Assessment (Finohta) [Training surgical skills with computer-based virtual reality simulators]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Training programming for healthcare professionals: How to support patients with chronic diseases to self-manage their health]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Trabecular micro bypass stent for glaucoma]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Trabecular bone score-TBS for bone fragility diagnosis]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Trabectedin (Yondelis) in the treatment of soft tissue sarcomas]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Trabectedin (Yondelis) in the treatment of soft tissue sarcomas]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Trabectedin (Yondelis) for the treatment of ovarian cancer]
2014     Health Council of the Netherlands Gezondheidsraad (GR) [Towards a sustainable tissue supply chain]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tovorafenib (low-grade glioma in paediatric patients) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2002     The Swedish Council on Health Technology Assessment (SBU) [Touch massage for dementia] - early assessment briefs (ALERT)
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Total hip arthroplasty (THA) using a short stem: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Total hip and knee artroplasties in Catalonia. Effectiveness and safety]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Total hip and knee arthroplasties in Catalonia. Effectiveness and safety]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Toripalimab (oesophageal carcinoma)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Toripalimab (nasopharyngeal carcinoma)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Toric intraocular lenses]
2017     Canary Health Service [Tools for early detection of disease-related malnutrition for adult population in the hospital setting]
2016     Andalusian Health Technology Assessment Area (AETSA) [Toolkit for the early awareness and alert systems in Spain (RedETS)]
2011     Andalusian Health Technology Assessment Area (AETSA) [Tool to assist in the decision-making of patients susceptible to dialysis]
2010     Andalusian Health Technology Assessment Area (AETSA) [Tool for the assessment of drugs for the treatment of inborn errors of metabolism. Gaucher disease]
2010     Andalusian Health Technology Assessment Area (AETSA) [Tool for the assessment of drugs for the treatment of inborn errors of metabolism. Anderson- Fabry disease]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tonsillotomy for recurrent acute tonsillitis and for hyperplasia of the tonsils]
2009     Committee for New Health Technology Assessment (CNHTA) [Tonsillectomy with coblation]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tonsillectomy or tonsillotomy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Tonsil surgery: comparison of intracapsular dissections and extracapsular dissections and dentification of children at risk for hemorrhage]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tolvaptan in autosomal dominant polycystic kidney disease]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Tolvaptan (Samsca) for the treatment of hyponatremia associated with the syndrome of inappropriate antidiuretic hormone secretion]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofersen (SOD1-associated amyotrophic lateral sclerosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Addendum to Commission A21-115]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Addendum A17-18]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tocilizumab in COVID-19 patients]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Tocilizumab for the treatment of rheumatoid arthritis]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [To test or not to test for thrombophilia after a first episode of venous thromboembolism: a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [To support the decision-making process concerning the end of an episode of care for adult users undergoing physical rehabilitation]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [TMNMT: Evidence report for the S3 guideline on chronic tinnitus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]